Loading...

GN Store Nord A/S

GNNDYPNK
Healthcare
Medical - Devices
$56.06
$-1.16(-2.03%)

GN Store Nord A/S (GNNDY) Financial Performance & Income Statement Overview

Review GN Store Nord A/S (GNNDY) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
-0.75%
0.75%
Operating Income Growth
114.04%
114.04%
Net Income Growth
333.33%
333.33%
Operating Cash Flow Growth
3.30%
3.30%
Operating Margin
9.15%
9.15%
Gross Margin
53.15%
53.15%
Net Profit Margin
4.56%
4.56%
ROE
7.68%
7.68%
ROIC
7.33%
7.33%

GN Store Nord A/S (GNNDY) Income Statement & Financial Overview

Access detailed annual and quarterly income data for GN Store Nord A/S GNNDY financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$3.99B$5.02B$4.16B$4.50B
Cost of Revenue$1.80B$2.35B$1.88B$2.25B
Gross Profit$2.19B$2.67B$2.28B$2.25B
Gross Profit Ratio$0.55$0.53$0.55$0.50
R&D Expenses$373.00M$355.00M$343.00M$442.00M
SG&A Expenses$1.52B-$1.91B$1.39B$1.52B
Operating Expenses$1.98B$2.07B$1.77B$2.05B
Total Costs & Expenses$3.77B$4.42B$3.65B$4.21B
Interest Income$121.00M$0.00$0.00$0.00
Interest Expense$228.00M$0.00$0.00$140.00M
Depreciation & Amortization$339.00M$326.00M$315.00M$413.00M
EBITDA$681.00M$875.00M$774.00M$700.00M
EBITDA Ratio$0.17$0.17$0.19$0.16
Operating Income$215.00M$601.00M$516.00M$284.00M
Operating Income Ratio$0.05$0.12$0.12$0.06
Other Income/Expenses (Net)-$101.00M-$98.00M-$145.00M-$140.00M
Income Before Tax$114.00M$503.00M$371.00M$144.00M
Income Before Tax Ratio$0.03$0.10$0.09$0.03
Income Tax Expense$25.00M$111.00M$82.00M$32.00M
Net Income$71.00M$367.00M$271.00M$96.00M
Net Income Ratio$0.02$0.07$0.07$0.02
EPS$0.49$2.52$1.86$0.66
Diluted EPS$0.49$2.52$1.86$0.66
Weighted Avg Shares Outstanding$145.61M$145.61M$145.61M$145.61M
Weighted Avg Shares Outstanding (Diluted)$145.61M$145.71M$145.68M$145.61M

Over the past four quarters, GN Store Nord A/S demonstrated steady revenue growth, increasing from $4.50B in Q2 2024 to $3.99B in Q1 2025. Operating income reached $215.00M in Q1 2025, maintaining a consistent 5% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $681.00M, reflecting operational efficiency. Net income dropped to $71.00M, with EPS at $0.49. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;